Quizartinib advances overall survival in acute myeloid leukaemia patients

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients

The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma

Lack of access to new cancer medicines in LMICs

Spotlight on global cancer control at ASCO 2022

ASCO 2022: Head and neck cancer highlights

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients

ASCO 2022: Breast cancer highlights